FORMA Therapeutics (Cambridge, MA) an oncology focused target discovery, screening, structural biology and small molecule developer, closed a $25M Series A funding financing. Participants include Novartis Option Fund and Bio*One Capital.
Biomics Biotechnologies (China) development-stage company focused on target identification and RNAi therapeutics, closed a $5M Series B financing. Participants include Jiangsu Dinghong Venture Capital and Jiangsu Benefit Rise Group.
Evolutionary Genomics (Lafayette, CO), a commercial-stage agricultural technology company with a proprietary gene discovery platform, closed a $3.0M Series A financing. Participants include Altira Group.